NCT06220864

SNV1521 in Participants With Advanced Solid Tumors

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Synnovation Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	SNV1521	SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
DRUG	DB-1310	DB-1310 is given as an infusion. Dose and frequency are dependent upon treatment arm.
DRUG	Abiraterone	Abiraterone is taken orally. Dose and frequency are per approved prescribing instructions.
DRUG	Darolutamide	Darolutamide is taken orally. Dose and frequency are per approved prescribing instructions.

Timeline

• Start date: 2024-02-23
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2024-01-24
• Last updated: 2026-04-14

Locations

21 sites across 6 countries: United States, Australia, Canada, France, Italy, Spain

Regulatory

• FDA-regulated drug study